Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Philip J Saylor

Showing results (11-20 of 50) with videos related to

Pageof 5
Sort By:
Journal of General Internal Medicine|October 20, 2009
Prostate cancer survivorship: prevention and treatment of the adverse effects of androgen deprivation therapyPhilip J Saylor, Nancy L Keating, Matthew R Smith
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 24, 2011
Emerging therapies to prevent skeletal morbidity in men with prostate cancerPhilip J Saylor, Richard J Lee, Matthew R Smith
AJR. American Journal of Roentgenology|May 25, 2011
Prostate cancer imaging: what surgeons, radiation oncologists, and medical oncologists want to knowShahin Tabatabaei, Philip J Saylor, John Coen, et al.
The Oncologist|September 19, 2014
Bone-targeting radiopharmaceuticals for the treatment of bone-metastatic castration-resistant prostate cancer: exploring the implications of new dataCharles J Ryan, Philip J Saylor, Jason J Everly, et al.
European Urology|February 23, 2013
Androgen-deprivation therapy and risk for biliary disease in men with prostate cancerPhilip J Saylor, Matthew R Smith, A James O'Malley, et al.
The Journal of Urology|April 20, 2010
Application of a fracture risk algorithm to men treated with androgen deprivation therapy for prostate cancerPhilip J Saylor, Donald S Kaufman, M Dror Michaelson, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|September 18, 2012
Multitargeted tyrosine kinase inhibition produces discordant changes between 99mTc-MDP bone scans and other disease biomarkers: analysis of a phase II study of sunitinib for metastatic castration-resistant prostate cancerPhilip J Saylor, Umar Mahmood, Anchisa Kunawudhi, et al.
The Journal of Urology|June 18, 2011
Factors associated with vertebral fractures in men treated with androgen deprivation therapy for prostate cancerPhilip J Saylor, Ronald A Morton, Michael L Hancock, et al.
Pituitary|April 9, 2021
GnRH agonist-associated pituitary apoplexy: a case series and review of the literatureFrancisco J Guarda, Xiaoling Yu, Naila Shiraliyeva, et al.
European Urology|December 4, 2012
New and emerging therapies for bone metastases in genitourinary cancersPhilip J Saylor, Andrew J Armstrong, Karim Fizazi, et al.
Pageof 5

Showing results (11-20 of 50) with videos related to

Sort By:
Pageof 5
Journal of General Internal Medicine|October 20, 2009
Prostate cancer survivorship: prevention and treatment of the adverse effects of androgen deprivation therapyPhilip J Saylor, Nancy L Keating, Matthew R Smith
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 24, 2011
Emerging therapies to prevent skeletal morbidity in men with prostate cancerPhilip J Saylor, Richard J Lee, Matthew R Smith
AJR. American Journal of Roentgenology|May 25, 2011
Prostate cancer imaging: what surgeons, radiation oncologists, and medical oncologists want to knowShahin Tabatabaei, Philip J Saylor, John Coen, et al.
The Oncologist|September 19, 2014
Bone-targeting radiopharmaceuticals for the treatment of bone-metastatic castration-resistant prostate cancer: exploring the implications of new dataCharles J Ryan, Philip J Saylor, Jason J Everly, et al.
European Urology|February 23, 2013
Androgen-deprivation therapy and risk for biliary disease in men with prostate cancerPhilip J Saylor, Matthew R Smith, A James O'Malley, et al.
The Journal of Urology|April 20, 2010
Application of a fracture risk algorithm to men treated with androgen deprivation therapy for prostate cancerPhilip J Saylor, Donald S Kaufman, M Dror Michaelson, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|September 18, 2012
Multitargeted tyrosine kinase inhibition produces discordant changes between 99mTc-MDP bone scans and other disease biomarkers: analysis of a phase II study of sunitinib for metastatic castration-resistant prostate cancerPhilip J Saylor, Umar Mahmood, Anchisa Kunawudhi, et al.
The Journal of Urology|June 18, 2011
Factors associated with vertebral fractures in men treated with androgen deprivation therapy for prostate cancerPhilip J Saylor, Ronald A Morton, Michael L Hancock, et al.
Pituitary|April 9, 2021
GnRH agonist-associated pituitary apoplexy: a case series and review of the literatureFrancisco J Guarda, Xiaoling Yu, Naila Shiraliyeva, et al.
European Urology|December 4, 2012
New and emerging therapies for bone metastases in genitourinary cancersPhilip J Saylor, Andrew J Armstrong, Karim Fizazi, et al.
Pageof 5